Targanta submits Marketing Authorization Application for oritavancin
Targanta Therapeutics Corporation announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead candidate, oritavancin, a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.
LONDON, Sept. 23, 2010-The European Medicines Agency today recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim.